{"entity":{"id":"idea-reg-closed-manufacturing-interop-standard","kind":"idea","name":"An open interoperability standard for closed automated cell-processing machines","aka":[],"tldr":"Each cell-therapy machine uses its own proprietary process and cartridges. A common standard would let a process run on any machine, like a document opening in any word processor.","summary":"Closed automated systems (Miltenyi CliniMACS Prodigy, Lonza Cocoon, Cellares Cell Shuttle, Ori Biotech and others) each lock a process to one platform, so a product validated on one cannot move without a full comparability exercise. The proposal is an open standard for process description (unit operations, parameters, in-process controls, data schema) and for consumable interfaces, maintained by a standards body with regulator participation, plus a shared comparability framework so that moving a validated process between compliant platforms requires a defined, reduced data package.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)","url":"https://doi.org/10.1001/jamaoncol.2018.0977"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["car-t","til-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-manufacturing-cell-therapy"],"keyPapers":["paper-hernandez-jama-oncol"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Products built to the standard can be transferred between compliant platforms with a comparability package a quarter the size of today's, and the number of manufacturing sites per approved cell therapy doubles within five years.","rationale":"Interoperability standards (DICOM in imaging, HL7 FHIR in records) unlocked competition and scale in adjacent fields. Vendor lock-in currently makes each cell-therapy process a single point of failure.","test":"Convene manufacturers, three device vendors and two regulators to publish version 1 of the standard, then demonstrate transfer of one CD19 CAR-T process between two compliant devices with side-by-side release data.","maturity":"speculative","actor":"engineering","cost":"medium","horizonYears":4},"route":"/ideas/idea-reg-closed-manufacturing-interop-standard/","neighbours":{"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"},{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"}],"paper":[{"id":"paper-hernandez-jama-oncol","kind":"paper","name":"Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy","route":"/key-papers/paper-hernandez-jama-oncol/"}]}}